Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma

Annals of Oncology

Volumn 8, Issue 10, 1997, Pages 1003-1008

  Raymond, E ^a,d   Burris, H A ^b   Rowinsky, E K ^a   Eckardt, J R ^a   Rodriguez, G ^a   Smith, L ^c   Weiss, G ^c   Von Hoff, D D ^a,e  

^a University of Texas Health Science Center at San Antonio   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e CTRC Institute for Drug Development   (United States)

Author keywords

Camptothecin derivative; Cisplatin; Combination chemotherapy; Platinum salts; Topotecan; Toxicity

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CISPLATIN; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; FEMALE; HUMAN; HYPOKALEMIA; HYPOTENSION; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0030720766     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008253314126     Document Type: Article

References (26)

1. Potmesil MP. Camptothecins: From bench research to hospital wards. Cancer Res 1994; 54: 1431-9.
2. Slichenmyer WJ, Rowinsky EK, Donehower RC et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271-91.
3. Chen AY, Liu LF. DNA topoisomerases: Essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 1994; 34: 1991-2218.
4. Hsiang Y-H, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
5. Ryan AJ, Squires S, Strutt HL et al. Camptothecin cytotoxicity in mammalian cells is associated with induction of persistent double strand breaks in replicating DNA. Nucl Acids Res 1991; 19: 3295-300.
6. Pommier Y, Leteurtre F, Fesen MR et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase I inhibitors. Cancer Invest 1994; 12: 530-42.
7. Von Hoff DD, Burris HA, Eckardt J et al. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994; 34 (Suppl): 41-5.
8. Burris HA, Hanauske A-R, Johnson RK et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992; 84: 1816-20.
9. Chou T-C, Motzer RJ, Tong Y et al. Computerized quantification of synergism and antagonism of taxol. topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-24.
10. Drewinko B, Loo TL, Green C. Combination chemotherapy in vitro with cis-dichlorodiammineplatinum (II). Cancer Treat Rep 1976; 63: 1619-25.
11. Johnson RK, McCabe FL, Yu Y. Combination regimens with topotecan in animal tumor models. Ann Oncol 1992; 3: 85 (Abstr).
12. Kaufman SH, Peereboom D, Buckwalter CA et al. Cytotoxic interactions between topotecan and diverse anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996; 88: 734-41.
13. Katz EJ, Vick JS, Kling KM et al. Effects of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma. Eur J Cancer 1990; 26: 724-7.
14. Creemers GJ, Bolis G, Gore M et al. Topotecan. an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996; 14: 3056-61.
15. Rowinsky EK, Grochou LB, Hendricks CB et al. Phase I and pharmacokinetic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-56.
16. Slichenmyer WJ, Rowinsky EK, Growchow LB et al. Camptothecin analogues: studies from The Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 1994; 34 (Suppl): 53-7.
17. LynchT. Topotecan today. J Clin Oncol 1996; 14: 3053-5.
18. Miller AA, Hargis JB, Lilenbaum RC et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A Cancer and Leukemia Group B study. J Clin Oncol 1994; 12: 2743-50.
19. Grochow LB, Rowinsky EK, Johnson R et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metabol Dispos 1992; 20: 706-13.
20. O'Reilly S, Rowinsky EK, Slichenmyer W et al. Phase I and pharmacokinetic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14: 3062-73.
21. Fukuda M, Nishio K, Kanzawa F et al. Synergy between cisplatin and topoisomerase I inhibitors, NB-506 and SN38 in human small cell lung cancer cells. Cancer Res 1996; 56: 789-93.
22. Mattern MR, Mong S-M, Bartus HF et al. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res 1987; 47: 1793-8.
23. Burkle A, Chen G, Kupper JH et al. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis 1993; 14: 559-61.
24. Bramson J, Prevost J, Malapetsa A et al. Poly(ADP-ribose) polymerase can bind melphalan damaged DNA. Cancer Res 1993; 53: 5370-3.
25. Miller A, Lilenbaum R, Lynch T et al. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol 1996; 14: 1964-5.
26. Rowinsky EK, Kaufmann SH, Baker SD et al. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996; 14: 3074-84.